Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 28, 2023 16:17 ET
|
Apollomics Inc.
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash,...
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
April 11, 2023 08:30 ET
|
Apollomics, Inc.
FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address...
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
March 30, 2023 08:00 ET
|
Apollomics, Inc.
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
November 15, 2022 08:00 ET
|
Apollomics, Inc.
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.
September 14, 2022 08:30 ET
|
Apollomics, Inc.
– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet...
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
July 26, 2022 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
January 12, 2022 07:05 ET
|
Apollomics, Inc.
FOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
January 04, 2022 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22, 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...